Abcely

Executive Summary

Abcely is a French biotechnology company founded in 2019 and headquartered in Paris, pioneering orally active secretory IgA (sIgA)-based immunotherapies. The company has developed a first-in-class platform to create biologic drugs designed specifically for mucosal cancers and chronic mucosal diseases. By enabling oral delivery to mucosal tissues, Abcely aims to overcome the limitations of traditional systemic antibody therapies, potentially offering a more targeted and convenient treatment approach. This platform represents a significant innovation in the biologics space, addressing a critical unmet need in mucosal disease management. Currently in the preclinical stage, Abcely is advancing its lead candidates toward IND-enabling studies. The company's focus on sIgA-based therapies leverages natural mucosal immunity, which could improve efficacy and reduce systemic side effects. While still early-stage and without disclosed funding or partnerships, Abcely's unique technology positions it well for future collaborations and financing. The biotech sector's growing interest in mucosal immunology and oral biologics provides a favorable landscape. Key upcoming milestones include completion of preclinical proof-of-concept studies and initiation of GLP toxicology, which could attract strategic partners or investors.

Upcoming Catalysts (preview)

• TBDCompletion of preclinical proof-of-concept studies60% success
• TBDSecuring Series A financing round50% success
• TBDEstablishment of a strategic partnership for development40% success